Evidence map›Paper›PMID 28931035›Full record

ArticlePloS one2017

Neuroprotection with hypothermia and allopurinol in an animal model of hypoxic-ischemic injury: Is it a gender question?

Javier Rodríguez-Fanjul, Cristina Durán Fernández-Feijóo, Míriam Lopez-Abad, Maria Goretti Lopez Ramos, Rafael Balada Caballé, Soledad Alcántara-Horillo, Marta Camprubí Camprubí

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
8.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Antioxidants (Basel, Switzerland) · 2020
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Javier Rodríguez-FanjulDepartment of Neonatology, BCNatal, Sant Joan de Déu-Hospital Clínic, Barcelona, Spain.
Cristina Durán Fernández-FeijóoDepartment of Neonatology, Hospital Álvaro Cunqueiro, EOXI, Vigo, Spain.
Míriam Lopez-AbadDepartment of Neonatology, BCNatal, Sant Joan de Déu-Hospital Clínic, Barcelona, Spain.
Maria Goretti Lopez RamosDepartment of Neonatology, BCNatal, Sant Joan de Déu-Hospital Clínic, Barcelona, Spain.
Rafael Balada CaballéDepartment of Pathology and Experimental Therapeutics, Faculty of Medicine and Biomedical Sciences, Bellvitge Campus, University of Barcelona, Barcelona, Spain.
Soledad Alcántara-HorilloDepartment of Pathology and Experimental Therapeutics, Faculty of Medicine and Biomedical Sciences, Bellvitge Campus, University of Barcelona, Barcelona, Spain.
Marta Camprubí CamprubíDepartment of Neonatology, BCNatal, Sant Joan de Déu-Hospital Clínic, Barcelona, Spain.ORCID http://orcid.org/0000-0001-9202-4664
Hospital Sant Joan de Déu Barcelona · ESUniversitat de Barcelona · ESUniversity Hospital Complex Of Vigo · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypoxic-ischemic encephalopathy (HIE) is one of the most important causes of neonatal brain injury. Therapeutic hypothermia (TH) is the standard treatment for term newborns after perinatal hypoxic ischemic injury (HI). Despite this, TH does not provide complete neuroprotection. Allopurinol seems to be a good neuroprotector in several animal studies, but it has never been tested in combination with hypothermia. Clinical findings show that male infants with (HI) fare more poorly than matched females in cognitive outcomes. However, there are few studies about neuroprotection taking gender into account in the results. The aim of the present study was to evaluate the potential additive neuroprotective effect of allopurinol when administrated in association with TH in a rodent model of moderate HI. Gender differences in neuroprotection were also evaluated.

methodsP10 male and female rat pups were subjected to HI (Vannucci model) and randomized into five groups: sham intervention (Control), no treatment (HI), hypothermia (HIH), allopurinol (HIA), and dual therapy (hypothermia and allopurinol) (HIHA). To evaluate a treatment's neuroprotective efficiency, 24 hours after the HI event caspase3 activation was measured. Damaged area and hippocampal volume were also measured 72 hours after the HI event. Negative geotaxis test was performed to evaluate early neurobehavioral reflexes. Learning and spatial memory were assessed via Morris Water Maze (MWM) test at 25 days of life.

resultsDamaged area and hippocampal volume were different among treatment groups (p = 0.001). The largest tissue lesion was observed in the HI group, followed by HIA. There were no differences between control, HIH, and HIHA. When learning process was analyzed, no differences were found. Females from the HIA group had similar results to the HIH and HIHA groups. Cleaved caspase 3 expression was increased in both HI and HIA. Despite this, in females cleaved caspase-3 was only differently increased in the HI group. All treated animals present an improvement in short-term (Negative geotaxis) and long-term (WMT) functional tests. Despite this, treated females present better long-term outcome. In short-term outcome no sex differences were observed.

conclusionsOur results suggest that dual therapy confers great neuroprotection after an HI event. There were functional, histological, and molecular improvements in all treated groups. These differences were more important in females than in males. No statistically significant differences were found between HIHA and HIH; both of them present a great improvement. Our results support the idea of different regulation mechanisms and pathways of cell death, depending on gender.

Indexed as

Disease Models, AnimalHypothermia, InducedAllopurinolAnimalsAnimals, NewbornAntimetabolitesCombined Modality TherapyFemaleHypoxia-Ischemia, BrainMaleNeuroprotectionNeuroprotective AgentsRats, WistarAllopurinolAntimetabolitesNeuroprotective Agents

Identifiers

PMID28931035
PMCPMC5606927
OpenAlexW2754611767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.